✦ LIBER ✦

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Scribed by Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Guardino, E.; Song, C.; Tong, B.; Ng, V.; Chu, Y.-W.; Perez, E. A.

Book ID: 118750015
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 205 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2012.44.9694

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

A phase 1 study of weekly dosing of tras

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

✍ Muralidhar Beeram; Ian E. Krop; Howard A. Burris; Sandhya R. Girish; Wei Yu; Mic 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

672 Randomised phase II trial (M77001) o

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

✍ J.-M. Extra; F. Cognetti; S. Chan; D. Maraninchi; R. Snyder; a. Lluch; M. Tubian 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Adding hormonal therapy to chemotherapy

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

✍ Naoki Hayashi, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Naoto T. Ueno 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 279 KB

A phase I/II prospective, single arm tri

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

✍ G. Somlo; C. L. Martel; S. K. Lau; P. Frankel; C. Ruel; L. Gu; A. Hurria; C. Chu 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 229 KB